林建廷

Cancer 2006;106:2657–63

55%

34%

5%

OS

25%Ph+

Standard risk

High risk

All pts

cHR pts

Risk stratification at diagnosis

Germany GMALL group◦ rt-PCR method, 105 pts in cHR with MRD(-) at enroll◦ No high WBC, not pro-B, pre-T, mature T, no poor

cyt◦ Median molecular to clinical relapse:9.5m

Blood. 2007;109:910-915

17/28(61%)

5/77(6%)

Haematologica 2008 Feb; 93(2):303-306.

Retrospective, 97 pts

Haematologica 2008 Feb; 93(2):303-306.

2-yr Leukemic-free survival Non-relapse mortality Relapse incidence

52%

42%

18%

18%@2yr for CR1 40%@2yr for CR1

HCT-CI is 0, and NRM~20%

Risk Groups

Low CML in CPRAAA

Int CML in APCML BP then CPAcute leukemia in remissionLymphoma in remissionRAEBCLLPNH

High CML in BPAcute leukemia in relapseLymphoma in relapseRAEB-tMyelomaSolid cancer

Category

Score Probability of Death

1 9-16 <25%

2 17-23 25-50%

3 24-30 50-75%

4 31-44 >75%

PAM score is:◦ 17 if RIST◦ 20 if myeloablative (non-TBI)◦ 24 if myeloablative

(TBI 12 Gy)